ORLANDO, FL / ACCESSWIRE / June 11, 2024 / PureCycle Technologies, Inc. (PCT) (NASDAQ:PCT), today, announced the receipt of a Letter of No Objection (LNO) from the United States Food & Drug ...

Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial. Story by Newsfile • 13h. V ancouver, British Columbia–(Newsfile Corp. – August 28, 2024) ...

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) ...

Defence Therapeutics Inc., a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection ...

TORONTO, Sept. 18, 2023 /PRNewswire/ - CELL Technologies Inc. is pleased to announce the award of a No Objection Letter (NOL) from Health Canada to launch the first ever pivotal stem cell program ...

The CSRC has also approved the registration of the REIT. ESR Group has received a no objection letter from the Shanghai Stock Exchange, advancing its plan to spin off its logistics assets into a ...

ORLANDO, FL / ACCESSWIRE / June 11, 2024 /PureCycle Technologies, Inc. (NASDAQ:PCT), today, announced the receipt of a Letter of No Objection (LNO) from the United States Food & Drug ...

Vancouver, British Columbia--(Newsfile Corp. - August 28, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a GMP-compliant, Health Canada-licensed ...

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...

TORONTO, Sept. 18, 2023 /PRNewswire/ - CELL Technologies Inc. is pleased to announce the award of a No Objection Letter (NOL) from Health Canada to launch the first ever pivotal stem cell program ...

ORLANDO, FL / ACCESSWIRE / June 11, 2024 / PureCycle Technologies, Inc. (NASDAQ:PCT), today, announced the receipt of a Letter of No Objection (LNO) from the United States Food & Drug ...